Figure 3
Immunotransplantation protects against systemic tumor burden. Donor mice received (A) no treatment or (B) CpG/CTX vaccination as described. On day 0 (7 days after the completion of the CpG/CTX vaccine), recipient mice received 9 Gy of TBI followed by transplantation of 5 × 106 BM cells and splenocytes from donors. Mice were challenged on day 1 after transplantation with 106 A20-LUC cells intravenously and followed clinically and per their bioluminescence. The same representative mice are shown over time. (C) Cohorts of recipient mice (n = 10) receiving the same treatments and tumor challenge with 106 wild-type A20 cells intravenously were followed for clinical signs of illness and survival.
